Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Abstract Background Choosing a safe disease modifying therapy during the COVID-19 pandemic is challenging. This case series study was conducted to determine the incidence rate and the course of Covid-19 infection in MS/NMOSD patients treated with Rituximab. Methods In this study, we designed a web-b...

Full description

Bibliographic Details
Main Authors: Sara Esmaeili, Mohammad Hossein Abbasi, Meysam Abolmaali, Mohammad Mojtahed, Seyedeh Niloufar Rafiei Alavi, Sevim Soleimani, Mahisa Mokhtari, Jaber Hatam, Samaneh Tanhapour Khotbehsara, Mohammad Reza Motamed, Mohammad Taghi Joghataei, Zahra Mirzaasgari, Mehdi Moghaddasi
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Neurology
Subjects:
COVID-19
Disease modifying therapy
Multiple sclerosis
MS
Neuromyelitis Optica
NMO
Online Access:https://doi.org/10.1186/s12883-021-02218-4

Internet

https://doi.org/10.1186/s12883-021-02218-4

Similar Items